摘要
目的探讨H2受体拮抗剂法莫替丁在预防奥氮平引起的体质量增加中的疗效。方法选择40例符合中国精神障碍分类与诊断标准的首发精神分裂症患者，随机分为奥氮平合用法莫替丁组和奥氮平合用安慰剂组，均治疗观察8周。于治疗前和治疗后2周、4周、8周测身高、体质量，计算体重指数（BMI）及8周内体质量增加超过自身基线体质量7％的患者比例。采用阳性症状评定量表（SAPS）和阴性症状评定量表（SANS）评定疗效。结果两组患者的体质量、BMI治疗后各时点均有增加，与治疗前比较差异有统计学意义（P〈0．05）。奥氮平加法莫替丁组和奥氮平组治疗8周末体质量分别增加了3．7kg，BMI各增加了2．5kg／cm^2和2．6kg／cm^2。治疗后各时点，两组患者的体质量、BMI增加程度比较差异无统计学意义（P〉0．05）。治疗8周末，体质量增加超过基线体质量7％的患者比例两组差异无统计学意义（P〉0．05）。治疗8周末，SAPS、SANS评分显著下降（P〈0．05）；SAPS与SANS分值与基线的差值无组间差异（P〉0．05）。结论合用H2-拮抗剂法莫替丁不能减轻奥氮平引起的体质量增加。
Objective To study the therapeutic effect of the H2 antagonist fomotidine on preventing weight gain olanzapine-induced. Methods Forty first-episode CCMD-3 .schizophrenia patients were randomly allocated to received either famotidine or placebo in addition to olanzapine, for 8 weeks. Their body weights and heights were measured before treatment and 2 weeks,4 weeks,8 weeks after treatment to calculate the body mass index and the percentage of patients gained more than 7 % of initial body weight after 8 weeks. SAPS and SANS were selected to evaluate the therapeutic effect. Results While the weight and the body mass index of patients in two groups after 2 weeks,4 weeks,8 weeks post-treatment increased significantly compared with those of pre-treatment（ P 〈 0,05 ）. The weight of patients in two groups gained 3.7kg at the end of 8 weeks, and the BMI increased 2.5 or 2.6kg/cm^2, respectively. However 8 weeks later, the difference be-tween two groups was not significant（P〈0.05）. The difference between two groups on the percentage of patients gained more than 7% of initial body weight at the end of 8 weeks was not significant（P〉0.05）.The scores of SAPS and SANS at the end of 8 weeks decreased significantly compared with those of the baseline（ P 〈 0.05 ）, but the difference between two groups was not significant（ P〉 0.05）, Conclusion Allocated to the H2 antagonist fomotidine could not reduce weight gain olanzapine-induced.
出处
《中国基层医药》
CAS
2008年第3期390-391,共2页
Chinese Journal of Primary Medicine and Pharmacy
